Furthermore, GravityFit will be set to
commercialise a range of smart functioning training garments for athletes and astronauts, which aim to stabilise and strengthen spine and joints, reduce the risk of injury and improve performance.
CANbridge also has exclusive rights to develop and
commercialise Puma biotechnology's Nerlynx (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China); a license with Apogenix to develop and
commercialise APG101 in greater China; a license (ex-North America) to develop and commercialize AVEO Oncology's ErbB3 inhibitory antibody candidate AV203 and an agreement with EUSA Pharma to
commercialise Caphosol for the prevention and treatment of oral mucositis caused by cancer treatments, for which it has received approval in China.
Under the terms of the agreement, Mylan will
commercialise Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.
United States-based Mylan has acquired an exclusive license to
commercialise a biosimilar to Humira (adalimumab), developed by Fujifilm Kyowa Kirin Biologics, in Europe, it was reported yesterday.
The terms of the agreement give Zeria the exclusive right to develop and
commercialise Veltassa in Japan once marketing authorisation has been granted.
M2 PHARMA-April 19, 2018-ArQule Licenses Basilea to Develop and
Commercialise for Derazantinib
It was reported yesterday that the contract has been signed to develop and
commercialise products featuring KP-470, an investigational compound for the topical treatment of psoriasis.
M2 PHARMA-April 13, 2018-Mylan acquires exclusive license to
commercialise biosimilar to Humira
It is reported today that the contract has been signed for the rights to develop and
commercialise the vTv's GLP-1r agonist program in China and other Pacific Rim countries.
Under the terms of the agreement, the two companies will work together to develop and
commercialise Lynparza, both as a monotherapy and as a combination treatment with other potential medicines.
Swiss pharmaceutical company Ewopharma revealed on Thursday the completion of the acquisition of the
commercialise rights for several products from Eisai Co Ltd (TYO:4523) in 11 countries in Central and Eastern Europe (CEE).
M2 PHARMA-February 14, 2018-Medison Pharma to
Commercialise Nerlynx (neratinib) in Israel
